Huntington's pipeline
Track Huntington's programs across gene therapy, antisense, allele-selective, and small-molecule huntingtin-lowering approaches.
Top programs in this hub
Starts with the highest-priority programs in the current dataset, then widens into the full bench below.
One of the most strategically important Huntington's programs because it represents a direct gene-therapy path rather than a small-molecule or ASO variant.
- Mechanism
- HTT-lowering gene therapy
- Modality
- AAV gene therapy
- Next catalyst
- Longer-run safety and functional read-throughs from treated cohorts.
- Last verified
- 20 Apr 2026
Huntingtin-lowering antisense program with unusually high field significance.
- Mechanism
- huntingtin-lowering antisense
- Modality
- ASO
- Next catalyst
- Updated data from the redesigned development path.
- Last verified
- 20 Apr 2026
A repeat-targeting oligonucleotide program that broadens the Huntington's pipeline beyond the biggest legacy names.
- Mechanism
- RNA modulation of expanded repeats
- Modality
- antisense oligonucleotide
- Next catalyst
- Safety, pharmacokinetic, and early pharmacodynamic read-throughs.
- Last verified
- 20 Apr 2026
What defines this bench
Quick pattern read on the mechanisms and modalities currently showing up most often.
A disease-specific view of the main programs, the common mechanisms, and the related program pages.
All tracked Huntington's disease programs
Every program in the current watchlist for this disease, in priority order.
One of the most strategically important Huntington's programs because it represents a direct gene-therapy path rather than a small-molecule or ASO variant.
- Mechanism
- HTT-lowering gene therapy
- Modality
- AAV gene therapy
- Next catalyst
- Longer-run safety and functional read-throughs from treated cohorts.
- Last verified
- 20 Apr 2026
Huntingtin-lowering antisense program with unusually high field significance.
- Mechanism
- huntingtin-lowering antisense
- Modality
- ASO
- Next catalyst
- Updated data from the redesigned development path.
- Last verified
- 20 Apr 2026
A repeat-targeting oligonucleotide program that broadens the Huntington's pipeline beyond the biggest legacy names.
- Mechanism
- RNA modulation of expanded repeats
- Modality
- antisense oligonucleotide
- Next catalyst
- Safety, pharmacokinetic, and early pharmacodynamic read-throughs.
- Last verified
- 20 Apr 2026
A major Huntington's program that deserves inclusion as part of the real clinical history of the field, not just the surviving winners.
- Mechanism
- sigma-1 receptor agonism
- Modality
- small molecule
- Next catalyst
- Mainly interpretation and strategic follow-through rather than a clean new expansion path.
- Last verified
- 20 Apr 2026
Small-molecule Huntington's program with mechanism-level significance if it continues to progress.
- Mechanism
- huntingtin mRNA splicing modulation
- Modality
- small molecule
- Next catalyst
- Further safety and target-engagement updates.
- Last verified
- 20 Apr 2026
An allele-selective Huntington's program that matters for the field's longer-run precision ambitions.
- Mechanism
- allele-selective HTT silencing
- Modality
- oligonucleotide
- Next catalyst
- How much of the allele-selective approach survives into future development strategy.
- Last verified
- 20 Apr 2026
Related pages
Research, key targets, Discover, and ways to contribute.
Other disease hubs
Other disease areas in the pipeline.
Track the mix of amyloid, tau, metabolic, and precision-style Alzheimer's programs worth watching.
Disease hub Parkinson's pipelineFollow Parkinson's programs spanning alpha-synuclein, GBA biology, gene therapy, and mechanistic repurposing.
Disease hub ALS pipelineTrack ALS programs across genetic targeting, stress-response biology, cell therapy, and platform-trial bets.
Disease hub FTD pipelineTrack FTD programs anchored in progranulin, GRN replacement, C9 biology, and other genetics-led strategies.